Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Zimmer Confirms Ongoing FDA Attention To Warsaw Plant

Executive Summary

Zimmer Biomet saw increased growth during the second quarter – but the company also confirmed on its recent Q2 earnings call that its quality remediation efforts continue, with fresh FDA observations arising from the agency's most recent inspection of one of Zimmer's Indiana-based manufacturing facilities.

You may also be interested in...

Zimmer Warning Letter Confirms Ongoing Issues With CAPA, Process Validation

US FDA has released a six-violation warning letter sent to a Zimmer Biomet facility in Warsaw, Ind. The company had already acknowledged that the letter was a possibility.

Ortho Roundup: Strong Knees Let SYK Stands Tall Against Recon Rivals ZMH, SNN And JNJ

The top four orthopedic implant makers have released their second-quarter and half-year results. Following DePuy Synthes report of a still-soft but recovering reconstructive implant market, this edition of Earnings Winners And Losers look at how the other three big recon players – Zimmer Biomet, Stryker, and Smith & Nephew fare. It also offers a peek into the top- and bottom-line results of the other key names within Medtech Insight's Top 10 orthopedic companies.

US FDA Finds Ongoing CAPA Issues In Zimmer Plant Reinspection

A follow-up inspection evaluating Zimmer Biomet’s progress in remediating issues documented in a 2016 FDA Form-483 uncovered 11 observations, eight of them repeats.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts